<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.99171</article-id><article-id pub-id-type="publisher-id">ACM-32294</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190900000_97742006.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  单中心维持性血透患者钙磷代谢情况及用药依从性分析
  Analysis of Calcium and Phosphorus Metabolism and Medication Compliance in Patients with Single-Center Maintenance Hemodialysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>余</surname><given-names>莹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>晓琴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>昆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>洁丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>江涛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>余</surname><given-names>晨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>同济大学附属同济医院肾内科，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>08</month><year>2019</year></pub-date><volume>09</volume><issue>09</issue><fpage>1113</fpage><lpage>1121</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨分析单中心维持性血液透析患者钙磷代谢情况，以及钙磷调节药物的用药情况。方法：选取2018年1月在同济大学附属同济医院医院血液净化中心行规律血液透析3个月以上的维持性血液透析患者为研究分析对象，回顾性分析患者透析前血磷、血钙、血白蛋白和全段甲状旁腺激素(iPTH)指标，分析钙、磷及iPTH达标情况，收集患者钙磷调节药物的用药情况，统计患者性别、年龄、透析龄、透析频率、磷结合剂、活性维生素D、钙剂等使用状况并进行统计学分析。结果：1) 患者平均校正血钙值为(2.25 &#177; 0.19) mmol/L，校正总钙低于目标标准共23例，占比为14.29%，达标者共131例占比为81.37%，7例患者高于标准值，占比为5.34%；平均血磷值为(1.68 &#177; 0.51) mmol/L，1例血磷指数比目标标准低，占比为0.61%，共52例达标，占比为32.29%，108例高于标准值，占比为67.08%；平均iPTH值为(341.65 &#177; 351.81) pg/ml，1例比目标标准低，占比为0.61%，共22例达标，占比为13.67，138例高于标准值占比为85.72 %。2) 患者服用钙磷调节药物的比例为68.32% (110/161)，Morisky平均得分为1.11 &#177; 1.387分。3) 单因素方差分析显示：不同年龄组患者血钙水平存在统计学差异，不同透析龄组患者的血iPTH水平存在统计学差异，Morisky评分得分不同的患者的血钙水平也存在统计学差异，但是卡方分析显示：在不同年龄组、透析龄组以及Morisky评分组，血钙、血磷和血iPTH的达标率均无统计学差异。4) 方差分析显示：Morisky评分在男性和女性之间以及不同透析龄之间无差别，在不同年龄组间存在差异，其中年龄小于35岁的患者得分明显高于其他年龄组。5) 相关性分析结果显示：iPTH与尿酸、钙、矫正钙、钙磷乘积、白蛋白水平、透析龄之间成正相关，iPTH与磷水平之间成负相关(p &lt; 0.05)。结论：根据KDIGO标准，我院该时期维持性透析患者的血钙达标率较高，而血磷和血iPTH水平未得到更好的控制；血钙水平与年龄和服药依从性相关，血iPTH水平与透析年限相关；年龄小的患者服药依次性低，而服药依从性高的患者血钙和血磷达标率高。临床需给予足够的重视，加强健康宣教。 Objective: To investigate and analyze the calcium and phosphorus metabolism in patients with single-center maintenance hemodialysis and the use of calcium and phosphorus regulating drugs. Methods: Maintenance hemodialysis patients who received regular hemodialysis for more than 3 months in the blood purification center of Tongji Hospital Affiliated to Tongji University in January 2018 were selected as the research and analysis objects. The indicators of serum phosphorus, serum calcium, serum albumin and whole parathyroid hormone (iPTH) before dialysis were ret-rospectively analyzed. The standards of calcium, phosphorus and iPTH, the medication status of calcium and phosphorus regulating drugs were collected. Results: 1) The mean corrected blood calcium of the patients was (2.25 &#177; 0.19) mmol/L, and the corrected total calcium was lower than the target standard in 23 cases, accounting for 14.29%, 131 cases of bidders accounting for 81.37%, and 7 cases of patients higher than the standard value, accounting for 5.34%. The average blood phosphorus was (1.68 &#177; 0.51) mmol/L. The blood phosphorus index of 1 case was lower than the target standard, accounting for 0.61%. A total of 52 cases reached the standard, accounting for 32.29%. The average iPTH was (341.65 &#177; 351.81) pg/ml, and 1 case was lower than the target standard, accounting for 0.61%. A total of 22 cases reached the standard, accounting for 13.67%, and 138 cases were higher than the standard value, accounting for 85.72%. 2) The proportion of patients taking calcium and phosphorus regulating drugs was 68.32% (110/161), and the average score of Morisky was 1.11 &#177; 1.387. 3) The single factor analysis of variance showed that different age group patients’ blood calcium level statistical differences, different dialysis age group of patients with serum iPTH statistical differences, Morisky scale scores in patients with different blood calcium level are statistically significant, but a chi-square analysis showed: in different age groups, dialysis age group and Morisky group, blood calcium, phosphorus and blood iPTH success rate had no statistical difference. 4) Anova showed that there was no difference in Morisky score between male and female and between different dialysis ages. There was difference among different age groups. Patients younger than 35 years old scored significantly higher than other age groups. 5) Correlation analysis showed that there was a positive correlation between iPTH and calcium, urate, correction calcium, calcium phosphorus product, albumin level and a negative correlation between iPTH and phosphorus level. Conclusion: According to the KDIGO standard, the compliance rate of serum calcium of maintenance dialysis patients in our hospital was higher during this period, while the levels of serum phosphorus and blood iPTH were not better controlled. Blood calcium level was correlated with age and medication compliance, and blood iPTH level was correlated with dialysis age. Younger patients were less likely to take medication in turn, while patients with higher compliance had higher compliance rates of blood calcium and phosphorus. Enough attention should be paid to health education in clinic. 
  
 
</p></abstract><kwd-group><kwd>维持性血液透析，血磷，血钙，iPTH，依从性, Maintenance Hemodialysis</kwd><kwd> Blood Phosphorus</kwd><kwd> Blood Calcium</kwd><kwd> iPTH</kwd><kwd> Compliance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>单中心维持性血透患者钙磷代谢情况及用药依从性分析<sup> </sup></title><p>余莹，张晓琴，张昆，黄洁丽，李江涛，余晨<sup>*</sup></p><p>同济大学附属同济医院肾内科，上海</p><disp-formula id="hanspub.32294-formula3"><graphic xlink:href="//html.hanspub.org/file/11-1571027x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年9月4日；录用日期：2019年9月17日；发布日期：2019年9月24日</p><disp-formula id="hanspub.32294-formula4"><graphic xlink:href="//html.hanspub.org/file/11-1571027x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨分析单中心维持性血液透析患者钙磷代谢情况，以及钙磷调节药物的用药情况。方法：选取2018年1月在同济大学附属同济医院医院血液净化中心行规律血液透析3个月以上的维持性血液透析患者为研究分析对象，回顾性分析患者透析前血磷、血钙、血白蛋白和全段甲状旁腺激素(iPTH)指标，分析钙、磷及iPTH达标情况，收集患者钙磷调节药物的用药情况，统计患者性别、年龄、透析龄、透析频率、磷结合剂、活性维生素D、钙剂等使用状况并进行统计学分析。结果：1) 患者平均校正血钙值为(2.25 &#177; 0.19) mmol/L，校正总钙低于目标标准共23例，占比为14.29%，达标者共131例占比为81.37%，7例患者高于标准值，占比为5.34%；平均血磷值为(1.68 &#177; 0.51) mmol/L，1例血磷指数比目标标准低，占比为0.61%，共52例达标，占比为32.29%，108例高于标准值，占比为67.08%；平均iPTH值为(341.65 &#177; 351.81) pg/ml，1例比目标标准低，占比为0.61%，共22例达标，占比为13.67，138例高于标准值占比为85.72 %。2) 患者服用钙磷调节药物的比例为68.32% (110/161)，Morisky平均得分为1.11 &#177; 1.387分。3) 单因素方差分析显示：不同年龄组患者血钙水平存在统计学差异，不同透析龄组患者的血iPTH水平存在统计学差异，Morisky评分得分不同的患者的血钙水平也存在统计学差异，但是卡方分析显示：在不同年龄组、透析龄组以及Morisky评分组，血钙、血磷和血iPTH的达标率均无统计学差异。4) 方差分析显示：Morisky评分在男性和女性之间以及不同透析龄之间无差别，在不同年龄组间存在差异，其中年龄小于35岁的患者得分明显高于其他年龄组。5) 相关性分析结果显示：iPTH与尿酸、钙、矫正钙、钙磷乘积、白蛋白水平、透析龄之间成正相关，iPTH与磷水平之间成负相关(p &lt; 0.05)。结论：根据KDIGO标准，我院该时期维持性透析患者的血钙达标率较高，而血磷和血iPTH水平未得到更好的控制；血钙水平与年龄和服药依从性相关，血iPTH水平与透析年限相关；年龄小的患者服药依次性低，而服药依从性高的患者血钙和血磷达标率高。临床需给予足够的重视，加强健康宣教。</p><p>关键词 :维持性血液透析，血磷，血钙，iPTH，依从性</p><disp-formula id="hanspub.32294-formula5"><graphic xlink:href="//html.hanspub.org/file/11-1571027x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/11-1571027x8_hanspub.png" /> <img src="//html.hanspub.org/file/11-1571027x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>维持性血液透析患者血清钙、磷紊乱和全段甲状旁腺激素(iPTH)分泌异常均可增加终末期肾病患者心血管事件的危险性 [<xref ref-type="bibr" rid="hanspub.32294-ref1">1</xref>]。本研究对单中心血液透析患者的临床资料进行了横断面调查，旨在了解维持性血液透析患者的钙磷代谢治疗达标率，并探讨其影响因素，以期为提高维持性血液透析患者的钙磷代谢控制水平和临床治疗获益提供依据。收集患者钙磷调节药物的用药情况和依从性情况，并进行相关分析。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>入选标准：2018年1月在上海市同济医院血液净化中心行规律血液透析3个月以上的维持性血液透析患者，排除肿瘤患者以及正处于严重感染期的患者。共入选161例，其中男97例，女64例；年龄25~92岁，平均年龄(63.61 &#177; 13.15)岁，患者在本院透析时间均&gt;3个月，维持性透析平均年龄为(4.84 &#177; 0.51)年，按患者透析慢性肾功能衰竭原发病：慢性肾小球肾炎83例，糖尿病肾病44例，高血压肾损害21例，多囊肾13例。所选研究对象均符合本研究课题。该研究获得同济大学附属同济医院伦理委员会的许可，并获得入选患者的知情同意。</p></sec><sec id="s4_2"><title>2.2. 研究方法</title><p>所有患者于透析前空腹抽取外周血，检测血清白蛋白、钙、磷及iPTH等指标，根据公式计算血清白蛋白校正钙(Ac-Ca)水平。按照KDIGO指南建议 [<xref ref-type="bibr" rid="hanspub.32294-ref2">2</xref>]，设定达标范围为血钙8.4~10.5 mg/dl (2.10~2.55 mmol/L)，血磷2.5~4.5 mg/dl (0.81~1.45 mmol/L)，iPTH100-600 pg/ml。采用问卷调查的方法收集患者的钙磷调节药物的使用情况和用药依从性情况。其中年龄分为&lt;35岁、35~60岁、60~80岁及&gt;80岁4组，透析龄分为0 (不到1年)、1~4年、5~9年、10~14年和15~20年5组，服药依从性采用Morisky评分表评定 [<xref ref-type="bibr" rid="hanspub.32294-ref2">2</xref>]，分为0分、1分、2分、3分和4分，分析患者血清钙、磷、iPTH水平和达标情况，并对患者年龄、透析龄和服药依从性等进行统计学分析。</p></sec><sec id="s4_3"><title>2.3. 统计方法</title><p>正态分布计量资料用均值 &#177; 标准差，非正态分布计量资料用四分位数表示；正态分布两组间比较用t检验，非正态分布两组间比较用非参数检验。计数资料用百分比表示，分类变量比较用卡方检验及Fisher检验。多组比较采用单因素方差分析。符合正态分布双变量简单线性相关分析用Person相关分析，非正态分布两变量简单线性相关分析用Spearman相关分析。P &lt; 0.05有统计学意义。所有统计计算均采用SPSS 21.0软件(SPSS Inc. USA)进行处理。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 基础资料分析</title><p>共入选患者161例，其中男97例，女64例；年龄25~92岁，平均年龄(63.61 &#177; 13.15)岁；C-反应蛋白(CRP)平均水平为8.95 &#177; 18.53 (mg/L)；平均血红蛋白水平为104.80 &#177; 15.25 (g/L)；尿酸平均水平为403.20 &#177; 78.33 (umol/L)；平均透析龄为4.84 &#177; 5.1年；透析充分性的百分比为71.43%，钙磷乘积平均值为47.03 &#177; 14.79 (表1)。按患者透析慢性肾功能衰竭原发病：慢性肾小球肾炎83例，糖尿病肾病44例，高血压肾损害21例，多囊肾13例(图1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General information of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >数值</th></tr></thead><tr><td align="center" valign="middle" >性别(男/女)</td><td align="center" valign="middle" >97/64</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >63.61 &#177; 13.15</td></tr><tr><td align="center" valign="middle" >CRP(mg/L)</td><td align="center" valign="middle" >8.95 &#177; 18.53</td></tr><tr><td align="center" valign="middle" >血红蛋白(g/L)</td><td align="center" valign="middle" >104.80 &#177; 15.25</td></tr><tr><td align="center" valign="middle" >尿酸(umol/L)</td><td align="center" valign="middle" >403.20 &#177; 78.33</td></tr><tr><td align="center" valign="middle" >透析龄(岁)</td><td align="center" valign="middle" >4.84 &#177; 5.11</td></tr><tr><td align="center" valign="middle" >spK/tv</td><td align="center" valign="middle" >2.2 &#177; 6.64</td></tr><tr><td align="center" valign="middle" >URR</td><td align="center" valign="middle" >70.39 &#177; 11.44</td></tr><tr><td align="center" valign="middle" >透析充分性(%)</td><td align="center" valign="middle" >71.43 (115/161)</td></tr><tr><td align="center" valign="middle" >钙磷乘积</td><td align="center" valign="middle" >47.03 &#177; 14.79</td></tr></tbody></table></table-wrap><p>表1. 患者的一般资料</p><p>图1. 透析患者的原发病</p></sec><sec id="s5_2"><title>3.2. 血钙水平及达标分析</title><p>患者平均校正血钙值为(2.25 &#177; 0.19) mmol/L，参照KDIGO标准校正总钙低于目标标准共23例，占比为14.29%，达标者共131例占比为81.37%，7例患者高于标准值，占比为5.34% (表2)；各年龄组患者血钙水平差异有统计学意义，但是血钙达标率无差异(表3)；各透析龄组患者血钙水平差异无统计学意义(表4)，血钙达标率亦无差异；不同Morisky评分患者血钙水平差异有统计学意义，但是血钙达标率无差异(表5)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Serum calcium and phosphorus metabolism and iPTH levels of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >标准范围</th><th align="center" valign="middle" >低于标准范围(%)</th><th align="center" valign="middle" >达到标准范围(%)</th><th align="center" valign="middle" >高于标准范围(%)</th></tr></thead><tr><td align="center" valign="middle" >血钙(mmol/L)</td><td align="center" valign="middle" >2.10~2.55</td><td align="center" valign="middle" >14.29</td><td align="center" valign="middle" >81.37</td><td align="center" valign="middle" >5.34</td></tr><tr><td align="center" valign="middle" >血磷(mmol/L)</td><td align="center" valign="middle" >0.81~1.45</td><td align="center" valign="middle" >0.61</td><td align="center" valign="middle" >32.29</td><td align="center" valign="middle" >67.08</td></tr><tr><td align="center" valign="middle" >iPTH水平(pg/ml)</td><td align="center" valign="middle" >150~600</td><td align="center" valign="middle" >32.30</td><td align="center" valign="middle" >50.31</td><td align="center" valign="middle" >15.47</td></tr></tbody></table></table-wrap><p>表2. 患者的钙磷代谢和iPTH水平达标状况</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Serum calcium levels of patients in each age grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >&lt;35岁(a)</th><th align="center" valign="middle" >35~60岁(b)</th><th align="center" valign="middle" >60~80岁(c)</th><th align="center" valign="middle" >&gt;80岁(d)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >矫正血钙(mmol/L)</td><td align="center" valign="middle" >2.32 &#177; 0.09</td><td align="center" valign="middle" >2.20 &#177; 0.22</td><td align="center" valign="middle" >2.26 &#177; 0.16</td><td align="center" valign="middle" >2.3 &#177; 0.19</td><td align="center" valign="middle" >0.02</td></tr><tr><td align="center" valign="middle" >血钙达标率(%)</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >77.80</td><td align="center" valign="middle" >82.20</td><td align="center" valign="middle" >85.7</td><td align="center" valign="middle" >0.63</td></tr></tbody></table></table-wrap><p>表3. 患者各年龄组血钙水平</p><p>备注：P值代表多重比较值，其中各组两两比较中：矫正血钙的a组与b、c、d比较无统计学差异，b组与c组比较有统计学差异p = 0.02，b与d组比较有统计学差异p = 0.05，c组与d组比较无统计学差异。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Serum calcium levels of patients in each dialysis age grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >0年(a)</th><th align="center" valign="middle" >1~4年 (b)</th><th align="center" valign="middle" >5~9年(c)</th><th align="center" valign="middle" >10~14年(d)</th><th align="center" valign="middle" >15~20年(e)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >矫正血钙(mmol/L)</td><td align="center" valign="middle" >2.19 &#177; 0.03</td><td align="center" valign="middle" >2.25 &#177; 0.02</td><td align="center" valign="middle" >2.25 &#177; 0.03</td><td align="center" valign="middle" >2.30 &#177; 0.06</td><td align="center" valign="middle" >2.34 &#177; 0.06</td><td align="center" valign="middle" >0.11</td></tr><tr><td align="center" valign="middle" >血钙达标率(%)</td><td align="center" valign="middle" >81.00</td><td align="center" valign="middle" >87.00</td><td align="center" valign="middle" >76.50</td><td align="center" valign="middle" >81.00</td><td align="center" valign="middle" >70.00</td><td align="center" valign="middle" >0.64</td></tr></tbody></table></table-wrap><p>表4. 患者各透析龄组血钙水平</p><p>备注：P值代表多重比较值，其中各组两两比较中：矫正血钙的a组与b、c比较无统计学差异，a组与d组比较有统计学差异p = 0.034，a与e组比较有统计学差异p = 0.03，b组与c、d、e组比较无统计学差异。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Serum calcium levels of patients with different Morisky evaluation group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >0分(a)</th><th align="center" valign="middle" >1分(b)</th><th align="center" valign="middle" >2分(c)</th><th align="center" valign="middle" >3分(d)</th><th align="center" valign="middle" >4分(e)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >矫正血钙(mmol/L)</td><td align="center" valign="middle" >2.29 &#177; 0.02</td><td align="center" valign="middle" >2.12 &#177; 0.05</td><td align="center" valign="middle" >2.22 &#177; 0.03</td><td align="center" valign="middle" >2.38 &#177; 0.09</td><td align="center" valign="middle" >2.19 &#177; 0.04</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >血钙达标率(%)</td><td align="center" valign="middle" >79.10</td><td align="center" valign="middle" >83.30</td><td align="center" valign="middle" >85.40</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >78.90</td><td align="center" valign="middle" >0.82</td></tr></tbody></table></table-wrap><p>表5. 患者不同Morisky评分组血钙水平</p><p>备注：P值代表多重比较值，其中各组两两比较中：矫正血钙的a组与c、d比较无统计学差异，a组与b组比较有统计学差异p = 0.004，a与e组比较有统计学差异p=0.049，b组与c、e组比较无统计学差异，b组与d组比较有统计学差异p = 0.034。</p></sec><sec id="s5_3"><title>3.3. 血磷水平及达标分析</title><p>平均血磷值为(1.68 &#177; 0.513) mmol/L，按KDIGO标准计算有1例血磷指数比目标标准低，占比为0.61%，共52例达标，占比为32.29%，108例高于标准值，占比为67.08% (表2)；各年龄组患者血磷水平和血磷达标率差异无统计学意义(表6)；各透析龄组患者血磷水平和血磷达标率均无差异(表7)；不同Morisky评分患者血磷水平和血磷达标率差异无统计学意义(表8)。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Serum phosphorus levels of patients in each age grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >&lt;35岁(a)</th><th align="center" valign="middle" >35~60岁(b)</th><th align="center" valign="middle" >60~80岁(c)</th><th align="center" valign="middle" >&gt;80岁(d)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >血磷(mmol/L)</td><td align="center" valign="middle" >2.30 &#177; 0.30</td><td align="center" valign="middle" >1.76 &#177; 0.06</td><td align="center" valign="middle" >1.60 &#177; 0.05</td><td align="center" valign="middle" >1.62 &#177; 0.109</td><td align="center" valign="middle" >0.03</td></tr><tr><td align="center" valign="middle" >血磷达标率(%)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >30.20</td><td align="center" valign="middle" >35.60</td><td align="center" valign="middle" >33.30</td><td align="center" valign="middle" >0.49</td></tr></tbody></table></table-wrap><p>表6. 患者各年龄组血磷水平</p><p>备注：P值代表多重比较值，其中各组两两比较中：血磷的a组与b、c、d比较均有统计学差异，分别p = 0.039，p = 0.008，p = 0.015，b组与c、d组比较无统计学差异。c组与d组比较无统计学差异。</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Serum phosphorus levels of patients in each dialysis age grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >0年(a)</th><th align="center" valign="middle" >1~4年(b)</th><th align="center" valign="middle" >5~9年(c)</th><th align="center" valign="middle" >10~14年(d)</th><th align="center" valign="middle" >15~20年(e)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >血磷(mmol/L)</td><td align="center" valign="middle" >1.66 &#177; 0.08</td><td align="center" valign="middle" >1.81 &#177; 0.07</td><td align="center" valign="middle" >1.64 &#177; 0.08</td><td align="center" valign="middle" >1.47 &#177; 0.11</td><td align="center" valign="middle" >1.67 &#177; 0.14</td><td align="center" valign="middle" >0.13</td></tr><tr><td align="center" valign="middle" >血磷达标率(%)</td><td align="center" valign="middle" >35.70</td><td align="center" valign="middle" >31.50</td><td align="center" valign="middle" >35.30</td><td align="center" valign="middle" >23.80</td><td align="center" valign="middle" >30.00</td><td align="center" valign="middle" >0.89</td></tr></tbody></table></table-wrap><p>表7. 患者各透析龄组血磷水平</p><p>备注：血磷各组多重比较中，均无统计学差异。</p><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Serum phosphorus levels of patients with different Morisky evaluation group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >0分(a)</th><th align="center" valign="middle" >1分(b)</th><th align="center" valign="middle" >2分(c)</th><th align="center" valign="middle" >3分(d)</th><th align="center" valign="middle" >4分(e)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >血磷(mmol/L)</td><td align="center" valign="middle" >1.73 &#177; 0.06</td><td align="center" valign="middle" >1.64 &#177; 0.12</td><td align="center" valign="middle" >1.64 &#177; 0.07</td><td align="center" valign="middle" >1.65 &#177; 0.23</td><td align="center" valign="middle" >1.59 &#177; 0.14</td><td align="center" valign="middle" >0.80</td></tr><tr><td align="center" valign="middle" >血磷达标率(%)</td><td align="center" valign="middle" >31.4</td><td align="center" valign="middle" >41.7</td><td align="center" valign="middle" >39．00</td><td align="center" valign="middle" >33.3</td><td align="center" valign="middle" >15.8</td><td align="center" valign="middle" >0.44</td></tr></tbody></table></table-wrap><p>表8. 患者不同Morisky评分组血磷水平</p><p>备注：血磷各组多重比较中，均无统计学差异。</p></sec><sec id="s5_4"><title>3.4. iPTH水平及达标分析</title><p>平均iPTH值为(341.65 &#177; 351.81) pg/ml，按KDIGO标准计算有1例比目标标准低，占比为0.61%，共22例达标，占比为13.67，138例高于标准值占比为85.72% (表2)；各年龄组患者血iPTH水平以及血iPTH达标率差异无统计学意义(表9)；各透析龄组患者血iPTH水平差异存在统计学意义，血iPTH达标率无差异(表10)；不同Morisky评分患者血iPTH水平差异无统计学意义，但是血iPTH达标率无差异(表11)。</p><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Serum iPTH levels of patients in each age grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >&lt;35岁(a)</th><th align="center" valign="middle" >35~60岁(b)</th><th align="center" valign="middle" >60~80岁(c)</th><th align="center" valign="middle" >&gt;80岁(d)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >iPTH(pg/ml)</td><td align="center" valign="middle" >384.9 &#177; 29.81</td><td align="center" valign="middle" >331.00 &#177; 37</td><td align="center" valign="middle" >331.55 &#177; 36.56</td><td align="center" valign="middle" >400.44 &#177; 126.29</td><td align="center" valign="middle" >0.86</td></tr><tr><td align="center" valign="middle" >iPTH达标率(%)</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >42.9</td><td align="center" valign="middle" >53.40</td><td align="center" valign="middle" >61.90</td><td align="center" valign="middle" >0.42</td></tr></tbody></table></table-wrap><p>表9. 患者各年龄组血iPTH水平</p><p>备注：血iPTH各组多重比较中，均无统计学差异。</p><table-wrap id="table10" ><label><xref ref-type="table" rid="table1">Table 1</xref>0</label><caption><title> Serum iPTH levels of patients in each dialysis age grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >0年(a)</th><th align="center" valign="middle" >1~4年(b)</th><th align="center" valign="middle" >5~9年(c)</th><th align="center" valign="middle" >10~14年(d)</th><th align="center" valign="middle" >15~20年(e)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >iPTH(pg/ml)</td><td align="center" valign="middle" >216.02 &#177; 28.75</td><td align="center" valign="middle" >303.12 &#177; 37.36</td><td align="center" valign="middle" >403.12 &#177; 48.98</td><td align="center" valign="middle" >538.33 &#177; 141.15</td><td align="center" valign="middle" >455.31 &#177; 129.54</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >iPTH达标率(%)</td><td align="center" valign="middle" >52.40</td><td align="center" valign="middle" >50.00</td><td align="center" valign="middle" >50.00</td><td align="center" valign="middle" >47.60</td><td align="center" valign="middle" >50.00</td><td align="center" valign="middle" >0.99</td></tr></tbody></table></table-wrap><p>表10. 患者各透析龄组血iPTH水平</p><p>备注：P值代表多重比较值，其中各组两两比较中：血磷的a组与b组比较无统计学差异、a组与c、d、e组比较均有统计学差异，分别p = 0.018，p = 0.001，p = 0.047， b组与c比较有统计学差异，p = 0.008，b组与d、e组比较无统计学差异，d与e组比较无统计学差异。</p><table-wrap id="table11" ><label><xref ref-type="table" rid="table1">Table 1</xref>1</label><caption><title> Serum iPTH levels of patients in different Morisky evaluation group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >0分(a)</th><th align="center" valign="middle" >1分(b)</th><th align="center" valign="middle" >2分(c)</th><th align="center" valign="middle" >3分(d)</th><th align="center" valign="middle" >4分(e)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >iPTH(pg/ml)</td><td align="center" valign="middle" >360.38 &#177; 43.63</td><td align="center" valign="middle" >318.09 &#177; 75.40</td><td align="center" valign="middle" >317.84 &#177; 43.03</td><td align="center" valign="middle" >157.62 &#177; 73.68</td><td align="center" valign="middle" >352.13 &#177; 74.6</td><td align="center" valign="middle" >0.86</td></tr><tr><td align="center" valign="middle" >iPTH达标率(%)</td><td align="center" valign="middle" >45.30</td><td align="center" valign="middle" >58.30</td><td align="center" valign="middle" >53.70</td><td align="center" valign="middle" >66.70</td><td align="center" valign="middle" >57.90</td><td align="center" valign="middle" >0.72</td></tr></tbody></table></table-wrap><p>表11. 患者不同Morisky评分组血iPTH水平</p><p>备注：血iPTH各组多重比较中，均无统计学差异。</p></sec><sec id="s5_5"><title>3.5. 患者钙磷调节药物服用依从性分析</title><p>患者服用钙磷调节药物的比例为68.32% (110/161)，其中醋酸钙44.72% (72/161)，碳酸钙12.42% (20/161)，骨化三醇19.88% (20/161)，其余服用碳酸镧、司维拉姆、西那卡塞。采用Morisky问卷调查患者用药依从性(分数越高，服药依从性越差)，平均得分为1.11 &#177; 1.38，其中得0分的比例为53.42% (86/161)，1分为7.45% (12/161)，2分为25.47% (41/161)，3分为1.86% (3/161)，4分为11.80% (19/161)。Morisky评分在不同性别之间无差异(表12)；在不同年龄组间存在统计学差异，其中年龄小于35岁的患者得分明显高于其他年龄组(表13)；在不同透析龄组之间的差别无统计学意义(表14)。</p><table-wrap id="table12" ><label><xref ref-type="table" rid="table1">Table 1</xref>2</label><caption><title> Morisky scores of patients of different gender</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >女(N = 64)</th><th align="center" valign="middle" >男(N = 97)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >Morisky评分(分)</td><td align="center" valign="middle" >(0.79, 1.46)</td><td align="center" valign="middle" >(0.82, 1.39)</td><td align="center" valign="middle" >0.92</td></tr></tbody></table></table-wrap><p>表12. 患者不同性别的Morisky评分</p><table-wrap id="table13" ><label><xref ref-type="table" rid="table1">Table 1</xref>3</label><caption><title> Morisky scores of patients in different age group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >&lt;35岁(a)</th><th align="center" valign="middle" >35~60岁(b)</th><th align="center" valign="middle" >60~80岁(c)</th><th align="center" valign="middle" >&gt;80岁(d)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >Morisky评分(分)</td><td align="center" valign="middle" >2.75 &#177; 0.48</td><td align="center" valign="middle" >1.35 &#177; 0.18</td><td align="center" valign="middle" >0.88 &#177; 0.15</td><td align="center" valign="middle" >0.90 &#177; 0.26</td><td align="center" valign="middle" >0.03</td></tr></tbody></table></table-wrap><p>表13. 患者不同年龄组的Morisky评分</p><table-wrap id="table14" ><label><xref ref-type="table" rid="table1">Table 1</xref>4</label><caption><title> Morisky scores of patients in different dialysis age group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >0年(a)</th><th align="center" valign="middle" >1~4年 (b)</th><th align="center" valign="middle" >5~9年(c)</th><th align="center" valign="middle" >10~14年(d)</th><th align="center" valign="middle" >15~20年(e)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >Morisky评分(分)</td><td align="center" valign="middle" >(0.63, 1.61)</td><td align="center" valign="middle" >(0.72, 1.46)</td><td align="center" valign="middle" >(0.79, 1.68)</td><td align="center" valign="middle" >(0.62, 1.95)</td><td align="center" valign="middle" >(0.20, 1.0)</td><td align="center" valign="middle" >0.52</td></tr></tbody></table></table-wrap><p>表14. 患者不同透析龄组的Morisky评分</p></sec><sec id="s5_6"><title>3.6. 相关性分析</title><p>以整体为研究对象，进行双变量简单线性相关分析，发现iPTH与尿酸、钙、矫正钙、钙磷乘积、白蛋白水平、透析龄之间成正相关，iPTH与磷水平之间成负相关(表15)。</p><table-wrap id="table15" ><label><xref ref-type="table" rid="table1">Table 1</xref>5</label><caption><title> Correlation analysis between patients’ iPTH and various variable</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >r</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >尿酸</td><td align="center" valign="middle" >0.33</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >钙</td><td align="center" valign="middle" >0.233</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >矫正钙</td><td align="center" valign="middle" >0.178</td><td align="center" valign="middle" >0.024</td></tr><tr><td align="center" valign="middle" >磷</td><td align="center" valign="middle" >−0.155</td><td align="center" valign="middle" >0.049</td></tr><tr><td align="center" valign="middle" >钙磷乘积</td><td align="center" valign="middle" >0.281</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >白蛋白</td><td align="center" valign="middle" >0.159</td><td align="center" valign="middle" >0.044</td></tr><tr><td align="center" valign="middle" >透析龄</td><td align="center" valign="middle" >0.299</td><td align="center" valign="middle" >0</td></tr></tbody></table></table-wrap><p>表15. 患者iPTH与各变量之间的相关性</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>维持性血透患者普遍存在矿物质和骨代谢紊乱，CKD-MBD是血液透析患者的重要并发症之一 [<xref ref-type="bibr" rid="hanspub.32294-ref3">3</xref>]。钙磷代谢异常可引起骨外软组织异常磷酸钙沉积，而出现全身软组织，特别是心脑血管系统的异常钙化，增加心脑血管事件的风险和死亡率，严重影响着血液透析患者的生活质量 [<xref ref-type="bibr" rid="hanspub.32294-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.32294-ref5">5</xref>]。本文对本透析中心维持性血液透析患者进行钙磷等指标的横断面调查研究，分析其钙磷代谢的现状以及影响因素。</p><p>根据KDIGO标准 [<xref ref-type="bibr" rid="hanspub.32294-ref6">6</xref>]，我院该时期维持性透析患者的血钙达标率为81.37%，达标水平尚可，血iPTH达标率为50.31%，与国内报道相符，而血磷达标率仅为32.30%，与其它人 [<xref ref-type="bibr" rid="hanspub.32294-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.32294-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.32294-ref9">9</xref>] 报道相比达标率较低。提示血磷的控制情况较差。国外多中心的研究显示 [<xref ref-type="bibr" rid="hanspub.32294-ref10">10</xref>]，血透患者高血磷的发病率高达52%，而国内的报道发生率为81% [<xref ref-type="bibr" rid="hanspub.32294-ref11">11</xref>]。发生高磷的原因：1) 肾功能减退发生排泄磷的障碍，引起磷溜留。2) 甲状旁腺激素分泌增加，引起继发性的甲旁亢。3) 饮食中摄入含磷过多。不同年龄、透析龄以及Morisky评分分组的统计学结果显示，血钙分别在35岁~60岁、透析5~9年以及Morisky评分4分的患者中达标率最低，血磷分别在小于35岁、透析10~14年以及Morisky评分4分的患者中达标率最低，血iPTH分别在小于35岁、透析10~14年以及Morisky评分1分的患者中达标率最低。</p><p>血透患者的高磷血症有研究表明高磷血症与透析患者的生存质量密切相关 [<xref ref-type="bibr" rid="hanspub.32294-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.32294-ref13">13</xref>]。高血磷可以导致钙磷乘积增高，引起骨外软组织异常磷酸钙沉积，而出现全身软组织，特别是心脑血管系统的异常钙化和相应的功能失衡 [<xref ref-type="bibr" rid="hanspub.32294-ref14">14</xref>]。新近研究表明高血磷也是心脑血管疾病发生发展和心脑血管急性事件的独立危险因素 [<xref ref-type="bibr" rid="hanspub.32294-ref15">15</xref>]，血磷每升高1 mg/dl，急性心梗的危险性增加35% [<xref ref-type="bibr" rid="hanspub.32294-ref16">16</xref>]。血磷水平&gt;2.1 mmol/L的透析患者冠状动脉的疾病相对危险度要比&lt;2.1 mmol/L者高56%，血磷水平&gt;2.1 mmol/L者猝死的相对危险度增加27% [<xref ref-type="bibr" rid="hanspub.32294-ref17">17</xref>]。所以在临床工作中需要控制MHD患者血磷水平。另外本研究结果显示透龄在10~14年时，透龄越大，达标率越低，而在14年以上时患者平均血磷水平出现下降，达标率上升。这可能是随着透龄的延长，患者矿物质及骨代谢异常的并发症逐步显现，透龄在14年以上患者重视高磷的危害，治疗上更趋向积极。</p><p>目前国内的磷结合剂主要有：碳酸钙，醋酸钙，司维拉姆、用碳酸镧、西那卡塞等。其中前两者最常用。Morisky评分问卷量表显示超过半数的患者得到0分，提示服药依从性好，但是量表存在主观性，患者的回答可能存在自我“美化”的倾向。不同性别的患者服药依从性并无明显差别。不同年龄组和透析龄的Morisky评分情况可见随着年龄的增大，透析龄的增大，得分呈现下降的趋势，提示服药的依从性增强，说明随着年龄的增长以及透析年限的延长，患者对钙磷代谢异常的认识增多，更加重视维持钙磷代谢平衡，也就更加倾向于规律服药以及饮食控制。</p><p>血液透析患者钙磷代谢紊乱的纠正远未达到理想水平，究其原因主要是缺乏有效易行的办法。在临床上需要给予维持性血透患者足够的重视，加强健康宣教，指导患者合理饮食，增强他们磷结合剂的服药依从性，合理用药，才能更好地控制血透患者的钙磷代谢紊乱，提高透析患者的生存质量。</p></sec><sec id="s7"><title>基金项目</title><p>国家自然科学基金(81600523, 81873609)。</p></sec><sec id="s8"><title>文章引用</title><p>余 莹,张晓琴,张 昆,黄洁丽,李江涛,余 晨. 单中心维持性血透患者钙磷代谢情况及用药依从性分析Analysis of Calcium and Phosphorus Metabolism and Medication Compliance in Patients with Single-Center Maintenance Hemodialysis[J]. 临床医学进展, 2019, 09(09): 1113-1121. https://doi.org/10.12677/ACM.2019.99171</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.32294-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Slinin, Y., Foley, R.N. and Collins, A.J. (2005) Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Dis-ease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study. Journal of the American Society of Nephrology, 16, 1788-1793. &lt;br&gt;https://doi.org/10.1681/ASN.2004040275</mixed-citation></ref><ref id="hanspub.32294-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Morisky, D.E., Green, L.W. and Levine, D.M. (1986) Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence. Medical Care, 24, 67-74. &lt;br&gt;https://doi.org/10.1097/00005650-198601000-00007</mixed-citation></ref><ref id="hanspub.32294-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王莉, 李贵森, 刘志红. 慢性肾脏病矿物质和骨异常诊治指导[J]. 肾脏病与透析肾移植杂志, 2013, 22(6): 554-559.</mixed-citation></ref><ref id="hanspub.32294-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Floege, J., et al. (2011) Serum iPTH, Calcium and Phosphate, and the Risk of Mortality in a European Haemodialysis Population. Nephrology Dialysis Transplantation, 26, 1948-1955. &lt;br&gt;https://doi.org/10.1093/ndt/gfq219</mixed-citation></ref><ref id="hanspub.32294-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tomiyama, C., et al. (2006) The Impact of Traditional and Non-Traditional Risk Factors on Coronary Calcification in Pre-Dialysis Patients. Nephrology Dialy-sis Transplantation, 21, 2464-2471. &lt;br&gt;https://doi.org/10.1093/ndt/gfl291</mixed-citation></ref><ref id="hanspub.32294-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Moe, S.M. and Block, G.A. (2009) KDIGO Clinical Practice Guideline forthe Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Dis-ease-Mineral and Bone Disorder. Kidney International, 76, 130.</mixed-citation></ref><ref id="hanspub.32294-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">唐莉, 欧阳凌霞, 姜继光, 施翎, 冯微微, 吕敏, 姚许平. 维持性血液透析患者钙磷代谢现状的单中心横断面研究[J]. 现代实用医学, 2016, 28(4): 3.</mixed-citation></ref><ref id="hanspub.32294-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">方春天, 席蔡, 刘张, 刘飞. 单中心维持性血液透析患者矿物质——骨异常的调查分析[J]. 中国中西医结合肾病杂志, 2018. 19(12): 3.</mixed-citation></ref><ref id="hanspub.32294-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">徐起, 吴美, 军叶, 萍郝, 丽程, 王光, 高顾, 雷霆, 闾志, 朱云, 柴冰. 单中心维持性血液透析患者的钙磷代谢调查[J]. 临床肾脏病杂志, 2015, 15(3): 6.</mixed-citation></ref><ref id="hanspub.32294-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Arenas, M.D., et al. (2006) Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: Changes of Clinical Practices and Their Effects on Outcomes and Quality Standards in Three Haemodialysis Units. Nephrology Dialysis Transplantation, 21, 1663-1668. &lt;br&gt;https://doi.org/10.1093/ndt/gfl006</mixed-citation></ref><ref id="hanspub.32294-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">孙鲁英, 王梅, 杨莉. 终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J]. 北京大学学报(医学版), 2005, 37(2): 3.</mixed-citation></ref><ref id="hanspub.32294-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Foley, R.N., Collins, A.J., Herzog, C.A., Ishani, A. and Kalra, P.A. (2009) Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young Adults. Journal of the American Society of Nephrology, 20, 397-404.  
&lt;br&gt;https://doi.org/10.1681/ASN.2008020141</mixed-citation></ref><ref id="hanspub.32294-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Isakova, T., et al. (2009) Phosphorus Binders and Survival on Hemodialysis. Journal of the American Society of Nephrology, 20, 388-396. &lt;br&gt;https://doi.org/10.1681/ASN.2008060609</mixed-citation></ref><ref id="hanspub.32294-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Onufrak, S.J., et al. (2008) Phosphorus Levels Are Associated with Subclinical Atherosclerosis in the General Population. Atherosclerosis, 199, 424-431. &lt;br&gt;https://doi.org/10.1016/j.atherosclerosis.2007.11.004</mixed-citation></ref><ref id="hanspub.32294-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ritter, C.S. and Slatopolsky, E. (2016) Phosphate Tox-icity in CKD: The Killer among Us. Clinical Journal of the American Society of Nephrology, 11, 1088-1100. &lt;br&gt;https://doi.org/10.2215/CJN.11901115</mixed-citation></ref><ref id="hanspub.32294-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mohlenkamp, S., et al. (2007) Assessment of the Natural History of Coronary Artery Calcification and Identification of Its Determinants. Rationale of the 2nd Part of the Heinz Nixdorf Recall Study. Herz, 32, 108-120.</mixed-citation></ref><ref id="hanspub.32294-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Schlieper, G., et al. (2008) Vascular Access Calcification Predicts Mortality in Hemodialysis Patients. Kidney International, 74, 1582-1587. &lt;br&gt;https://doi.org/10.1038/ki.2008.458</mixed-citation></ref></ref-list></back></article>